Maximum quantity allowed is 999
Please select the quantity
CAS RN: 10238-21-8 | Product Number: G0382
Glibenclamide
×
![]()
×
Purity: >98.5%(T)(HPLC)
Synonyms:
- 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide
- Glyburide
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 5G |
NT$1,080
|
≥40 | 16 | Contact Us | |
| 25G |
NT$3,400
|
20 | 33 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | G0382 |
| Purity / Analysis Method | >98.5%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__3H__2__8ClN__3O__5S = 494.00 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 10238-21-8 |
| Reaxys Registry Number | 2230085 |
| PubChem Substance ID | 135726994 |
| Merck Index (14) | 4478 |
| MDL Number | MFCD00056625 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.5 area% |
| Purity(Neutralization titration) | min. 98.5 % |
| Melting point | 172.0 to 176.0 °C |
Properties (reference)
| Melting Point | 174 °C |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Dimethylformamide |
| Solubility (slightly sol. in) | Ethanol, Methanol |
GHS
Related Laws:
| RTECS# | YS4725200 |
Transport Information:
| H.S.code* | 2935.90-000 |
Application
Glibenclamide: A Sulfonylurea ATP-Dependent K+ Channel Antagonist
Glibenclamide belongs to sulfonylurea antidiabetics which increase the release of insulin from pancreatic B-cells. Sulfonylurea antidiabetics inhibit ATP-gated K+ channels and thereby cause depolarization of the B-cell membrane. The depolarization leads to activation of voltage-dependent Ca channels and Ca2+ influx into the B-cell, and eventually increases insulin release. Recently, a combination agent with metformin [M2009] is also used for the treatment of Type 2 diabetes. (The product is for research purpose only.)
References
- Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects (a review)
- Sulfonylurea receptor 2B and Kir6.1 form a sulfonylurea-sensitive but ATP-insensitive K+ channel
- Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide
- Sulfonylurea stimulation of insulin secretion (a review)
- Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes (a review)
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
- Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
- Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.